Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis

Exclusion Criteria

• •1. Subjects with any history of decompensated liver disease, including but not restricted to portal hypertension as manifested by gastroesophageal varices, variceal bleeding, ascites, or encephalopathy or a hepatic mass lesion suspicious for hepatocellular carcinoma (HCC).
• •2. Liver histology consistent with any other co-existing cause of chronic liver disease (apart from fatty liver).
• •3. Subjects who have been treated for HCV infection within 6 months before Screening.
• •4. Subjects who have been on any experimental protocol or therapy within 28 days before Screening.
• •5. Known HIV infection.
• •6. Chronic hepatitis B infection
• •7. Uncontrolled diabetes.
• •8. Unstable or uncontrolled thyroid disease
• •9. Uncontrolled seizures disorder.
• •10. History of malignant cancer within the last 5 years with the exception of localized basal or squamous cell carcinoma.
• •11. Alcohol and/or drug abuse within the past year.
• •12. Pregnant or lactating women or women who plan to become pregnant during the study.